Co-founder & Chief Executive Officer, Avenna
Nina is the co-founder and CEO of Avenna Ltd , a medtech company specialising in the development of precision medicine technologies for Chronic Inflammatory Diseases (CIDs).
Her mission is to make healthcare for CIDs more preventive and personalised. This can be achieved by developing more effective, affordable, and accessible precision medicine solutions, which enable early detection and treatment personalisation for CIDs. She has a background in finance, business, and healthcare and worked in large multinational companies including Nomura, Bloomberg and Schlumberger as well as several entrepreneurship ventures. Her first company, Wellcode Life is a scientific wellness company which provides integrated health transformation programmes tailored to an individual’s unique molecular, genetic and physiological profile.
Nina’s main ability and expertise is to connect clinical, science and business worlds. She uses wealth of experience to translate the most promising research-grade technologies into practical solutions for individuals, clinicians, and biopharma. This includes design and execution of clinical studies and trials, developing informatics infrastructure to facilitate the delivery of precision health programs for chronic disease prevention.